WA-ITRON
Itron, Inc. (NASDAQ: ITRI), which is innovating the way utilities and cities manage energy and water, released its 2021 Resourcefulness Insight Report detailing why modernizing energy infrastructure is the path to achieving a resilient and reliable grid that successfully mitigates the impacts of climate disruption, minimizes interruptions from natural disasters, integrates renewables and prepares for the increased adoption of electric vehicles (EVs). Preparing for the Unexpected and the Inevitable: An Itron Resourcefulness Report summarizes key findings from surveys of 500 utility executives and 500 informed consumers from across five countries – United States, Australia, France, Germany and Indonesia – on the key challenges, barriers and concerns facing utilities in the next five years.
Launched today at Itron Inspire 2021, the company’s premier customer-focused event, the report dives deep into the differing opinions of consumers and utility executives related to resilience planning for an innovative, reliable grid. Across the surveyed countries, integrating renewables and modernizing aging grid infrastructure are the top two biggest challenges. The findings indicate that in the next five years utility execs surveyed see EV demands becoming the biggest challenge for the grid. Additional key findings in the report show:
- Consumers agree with the top priorities of integrating renewables and upgrading infrastructures. However, they are more concerned about natural disasters (20%) than EVs (16%).
- Utility executives are extremely/very concerned about the grid and the impact of disasters (88%), demand from EVs (85%), integrating renewables (86%) and complying with environmental mandates (90%).
- Consumers are less concerned than utility executives about the impact of disasters and EVs on the grid, however they are also less confident in how prepared utilities are to manage these situations with 84% of utilities stating they are ready vs. 47% of consumers.
“In looking at these results, there is agreement on the need for grid modernization, but utility executives and consumers have different concerns and priorities. We see that utilities are looking to the future to plan and prepare for what is coming, while consumers indicated more immediate concerns,” said Marina Donovan, vice president of global marketing and public affairs. “Consumers remain concerned about how climate disruption – and the resulting rise in natural disasters – are impacting their lives, yet they are less aware or even unaware of the impact of EVs and renewables on the grid.”
Across all five countries, the biggest challenges to the reliability and resiliency of the grid are upgrading aging infrastructure, integrating renewables and complying with carbon mandates, but these priorities change as executives look to the future:
|
Today |
In Five Years |
US |
Upgrading grid |
Upgrading grid |
Australia |
Upgrading grid |
Meeting EV demand & upgrading grid |
France |
Integrating renewables |
Meeting EV demand |
Germany |
Complying with carbon mandates |
Meeting EV demand |
Indonesia |
Integrating renewables |
Integrating renewables |
According to the survey, the COVID-19 pandemic has delayed technology investments across all the countries. Yet, the technology is critical to create a more resilient infrastructure. The report notes that advanced metering infrastructure and distribution automation are high priorities for EVs, distributed energy resources (DER) deployments, and disaster response. And sensors are the highest priority technology for grid resiliency in the face of disasters.
“In America, the U.S. Senate passed a $1.2 trillion bipartisan infrastructure bill, which is currently being debated in the House of Representatives, that will be critical to driving grid modernization. Replacing aging electrical infrastructure is paramount to making the grid more resilient and reliable in the face of extreme weather conditions and climate disruption. This federal investment is needed to protect and prepare for disasters as well as sustainable growth,” added Donovan.
To download a full copy of the Itron Resourcefulness Insight Report, visit www.itron.com/resourceful . To listen to key sessions and keynotes at the virtual Itron Inspire Event, Oct. 4-6, please visit www.itron.com/inspire .
About Itron
Itron enables utilities and cities to safely, securely and reliably deliver critical infrastructure solutions to communities in more than 100 countries. Our portfolio of smart networks, software, services, meters and sensors helps our customers better manage electricity, gas and water resources for the people they serve. By working with our customers to ensure their success, we help improve the quality of life, ensure the safety and promote the well-being of millions of people around the globe. Itron is dedicated to creating a more resourceful world. Join us: www.itron.com .
Itron® is a registered trademark of Itron, Inc. All third-party trademarks are property of their respective owners, and any usage herein does not suggest or imply any relationship between Itron and the third party unless expressly stated.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211004005176/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
